TY - JOUR
T1 - Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP)
T2 - Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
AU - Mesa, Ruben A.
AU - Verstovsek, Srdan
AU - Cervantes, Francisco
AU - Barosi, Giovanni
AU - Reilly, John T.
AU - Dupriez, Brigitte
AU - Levine, Ross
AU - Le Bousse-Kerdiles, Marie Caroline
AU - Wadleigh, Martha
AU - Campbell, Peter J.
AU - Silver, Richard T.
AU - Vannucchi, Alessandro M.
AU - Deeg, H. Joachim
AU - Gisslinger, Heinz
AU - Thomas, Deborah
AU - Odenike, Olatoyosi
AU - Solberg, Lawrence A.
AU - Gotlib, Jason
AU - Hexner, Elizabeth
AU - Nimer, Stephen D.
AU - Kantarjian, Hagop
AU - Orazi, Attilio
AU - Vardiman, James W.
AU - Thiele, Juergen
AU - Tefferi, Ayalew
N1 - Funding Information:
The current work is a summary of the proceedings from the second IWG-MRT meeting held in Houston, TX, USA, November 18, 2006. The meeting was jointly organized by the MD Anderson Cancer Center, Leukemia Department, and the Mayo Clinic, Myeloproliferative Disease Group. Supported by the Joe W. and Dorothy Dorsett Brown Foundation (Metairie, LA). A complete list of the IWG-MRT members and their affiliation is found in Appendix 1 of the manuscript.
PY - 2007/6
Y1 - 2007/6
N2 - The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists and its main goal is to provide a forum for scientific exchange and collaboration. During its first general meeting in April 2006, the IWG-MRT established uniform treatment response criteria for chronic idiopathic myelofibrosis (CIMF); also known as agnogenic myeloid metaplasia (AMM), myelofibrosis with myeloid metaplasia (MMM), and many other names in the hematologic literature. This document summarizes the proceedings from the second meeting of the IWG-MRT, in November 2006, where the group discussed and agreed to standardize the nomenclature referring to CIMF: (i) the term primary myelofibrosis (PMF) was chosen over several other designations including CIMF, AMM, and MMM, (ii) myelofibrosis that develops in the setting of either polycythemia vera (PV) or essential thrombocythemia (ET) will be referred to as post-PV MF and post-ET MF, respectively, and (iii) "leukemic" transformation will be recognized as blast phase disease (PMF-BP, post-PV/ET MF in blast phase).
AB - The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists and its main goal is to provide a forum for scientific exchange and collaboration. During its first general meeting in April 2006, the IWG-MRT established uniform treatment response criteria for chronic idiopathic myelofibrosis (CIMF); also known as agnogenic myeloid metaplasia (AMM), myelofibrosis with myeloid metaplasia (MMM), and many other names in the hematologic literature. This document summarizes the proceedings from the second meeting of the IWG-MRT, in November 2006, where the group discussed and agreed to standardize the nomenclature referring to CIMF: (i) the term primary myelofibrosis (PMF) was chosen over several other designations including CIMF, AMM, and MMM, (ii) myelofibrosis that develops in the setting of either polycythemia vera (PV) or essential thrombocythemia (ET) will be referred to as post-PV MF and post-ET MF, respectively, and (iii) "leukemic" transformation will be recognized as blast phase disease (PMF-BP, post-PV/ET MF in blast phase).
KW - Chronic idiopathic myelofibrosis
KW - IWG-MRT
KW - International Working Group for Myelofibrosis Research and Treatment
KW - Myelofibrosis
KW - Myelofibrosis with myeloid metaplasia
KW - Myeloproliferative disorders
KW - Primary myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=34248364065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248364065&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2006.12.002
DO - 10.1016/j.leukres.2006.12.002
M3 - Article
C2 - 17210175
AN - SCOPUS:34248364065
SN - 0145-2126
VL - 31
SP - 737
EP - 740
JO - Leukemia Research
JF - Leukemia Research
IS - 6
ER -